Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00191412 · ClinicalTrials.gov registry record · Phase 2
A Study of Pemetrexed in the Treatment of Patients With Advanced Metastatic Cancer of the Liver
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT00191412 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 41 participants.
The verdict
NCT00191412, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
This study is to assess the response rate, toxicity, time-to-event efficacy, and potential markers of pemetrexed in patients with liver cancer.
Interventions
- DRUG Pemetrexed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00191412
The ClinicalTrials.gov registry entry for NCT00191412 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pemetrexed is the first listed.
NCT00191412 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00191412 about?
NCT00191412 is a clinical study titled "A Study of Pemetrexed in the Treatment of Patients With Advanced Metastatic Cancer of the Liver". This study is to assess the response rate, toxicity, time-to-event efficacy, and potential markers of pemetrexed in patients with liver cancer.
What is the current status of trial NCT00191412?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2005-01. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00191412?
The interventions under investigation include: Pemetrexed (DRUG).
Who is sponsoring clinical trial NCT00191412?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.